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ABSTRACT
Objective To determine the incidence of and mortality
from bullous pemphigoid and pemphigus vulgaris in the
United Kingdom.
Design Retrospective historical cohort study.
Setting Computerised medical records from the health
improvement network, a large population based UK
general practice database.
Participants Patients with pemphigus vulgaris and
bullous pemphigoid diagnostic codes and age, sex, and
practice matched controls.
Main outcome measures Incidence and mortality
comparedwith the control population by calendar period,
age group, sex, geographical region, and degree of social
deprivation.
Results 869 people with bullous pemphigoid and 138
people with pemphigus vulgaris were identified. The
median age at presentation for bullous pemphigoid was
80 (range 23-102) years, and 534 (61%) patients were
female. The median age at presentation for pemphigus
vulgaris was 71 (21-102) years, and 91 (66%) patients
were female. Incidences of bullous pemphigoid and
pemphigus vulgaris were 4.3 (95% confidence interval
4.0 to 4.6) and 0.7 (0.6 to 0.8) per 100 000 person years.
The incidence of bullous pemphigoid increased over
time; the average yearly increase was 17% (incidence
rate ratio=1.2, 95% confidence interval 1.1 to 1.2). An
average yearly increase in incidence of pemphigus
vulgaris of 11% (incidence rate ratio=1.1, 1.0 to 1.2)
occurred. The risk of death for patients with bullous
pemphigoid was twice as great as for controls (adjusted
hazard ratio=2.3, 95% confidence interval 2.0 to 2.7).
For pemphigus vulgaris, the risk of deathwas three times
greater than for controls (adjusted hazard ratio=3.3, 2.2
to 5.2).
Conclusions Incidences of bullous pemphigoid and
pemphigus vulgaris are increasing. The reasons for
in incidence are not clearly understood but have
implications for identifying causative factors.
are associated with a high risk of death. Previous
estimates may have underestimated the risk of death
associated with these diseases.
INTRODUCTION
Little is known about the epidemiology of bullous
pemphigoid and pemphigus vulgaris.1 2 Both of these
autoimmune disorders, which cause blistering of the
skin and mucous membranes, need intensive manage-
ment by dermatologists in partnership with primary
care physicians and other specialties, including
ophthalmology and oral medicine, and disease man-
agement is often very challenging.
Previous studies of bullous pemphigoid have
reported incidences between 0.2 and 3 per 100 000
person years; these are higher in older age groups, and
some studies report associations with sex.2-4 In the
United Kingdom, a regional study estimated an
incidence of 1.4 per 100 000 person years.5 Wide
variation in mortality is reported, with one year
mortality varying between 6% in the United States
and 41% in France.67
In the fewhospital based studies of the epidemiology
of pemphigus vulgaris, the reported incidence varied
between 0.076 and 1.6 per 100 000 person years.8 9
Several studies have suggested a higher incidence in
women.910 No epidemiological data are available from
the UK. Before oral corticosteroids were used, this
disorder was fatal.11 Two hospital based studies report
one year mortality of 4.8% and 54%, with no clear
estimate of overall disease specific mortality.12 13
The published studies are mainly small and hospital
based; thus, although they have an excellent validity,
they are unlikely to represent the full spectrum of
disease. They are susceptible to selection bias, possibly
leading to underestimation of incidence and over-
estimation of mortality. We carried out a large
population based study in people with bullous
pemphigoid and pemphigus vulgaris to provide robust
data on incidence anddemographic data in theUKand
to resolve the controversies aboutmortality from these
diseases. This study gives a more general population
view of the impact of these diseases.
METHODS
The health improvement network is a computerised
longitudinal general practice database with demo-
graphic data similar to the general population. The
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version we used contained data from 328 general
practices that use “InPracticeVision” software. Several
studies have confirmed that the health improvement
network data are sufficiently accurate for use in
epidemiological research.14 15 The quality of the data
has beenvalidated against the general practice research
database, a data source for more than 250 peer
reviewed publications, and well confirmed disease
associations have been replicated.16
Study population
Between 1996 and 2006, we identified all patients with
a diagnosis of bullous pemphigoid or pemphigus
vulgaris from the health improvement network data-
base. In order to exclude prevalent cases,we imposed a
lag period of three months after registration with their
general practitioner. This method has been previously
validated by Lewis and colleagues to differentiate
between incident and prevalent cases of disorders that
present acutely.17 We selected a control group of up to
four controls per case, matched randomly by age, sex,
and general practice. Controls also had to be alive and
contributing data to the health improvement network
database on the date of diagnosis of the matched case.
We excluded people aged under 20 years from both
cases and controls, as both disorders are rare in this age
group and may represent different diseases. We
assigned a date of “pseudodiagnosis” to controls,
which was the date of diagnosis for the matched case.
Outcomes
We recorded incident diagnoses and dates of death.
The follow-up period began on the date of first
diagnosis or the date of “pseudodiagnosis” for controls.
Statistical analysis
Incidence—We calculated incidences by age, cate-
gorised into 10 year age bands; sex; and calendar
period. We used multivariate regression to model
incidence rate ratios, adjusting for changes in age, sex
structure, and calendar period over time. We applied
calculated incidences for both diseases to the UK
population totals for the years 2001-5 to estimate the
number of new cases a year.
Mortality—We identified all deaths in the two case
populations and matched controls and used Kaplan-
Meier techniques to calculate oneyearmortality and five
year survival rates.We used Cox regression to compare
themortality of cases andcontrols, adjusting for age, sex,
and calendar period.We usedNelson-Aalen plots to test
the proportional hazards assumption.
Office for National Statistics data—We calculated
expected numbers of incident cases and deaths for
both diseases by applying study rates to the Office for
National Statistics population (2001-5) and comparing
results with Office for National Statistics data.
Sample size and power calculations—Thedataset for this
study contained two million person years of data.
Assuming a total of 1000 cases, this study would have
90% statistical power to detect a hazard ratio for death
of 2.0 or greater in cases comparedwith controls, at the
5% level of significance.
RESULTS
Our cohort included 869 people with bullous pemphi-
goid contributing 1993 person years and 3453 matched
controls contributing 9765 person years. The median
age at first presentation for bullous pemphigoid was 80
(range 23-102) years (fig 1), and 534 (61%) patients were
women. One hundred and thirty eight people with
pemphigus vulgaris contributed 380 person years, and
551 matched controls contributed 1763 person years.
The median age at first presentation for pemphigus
vulgaris was 71 (21-102) years (fig 1), and 91 (66%)
patients were women. The median length of follow-up
for people with bullous pemphigoid was 1.6 (range 0-9)
years, and that for pemphigus vulgaris was 2.0 (0-10.4)
years. Losses to follow-up were similar in cases and
controls in both diseases (by the end of year 2, bullous
pemphigoid cases and controls 34% lost; pemphigus
vulgaris cases 30% lost, controls 31% lost) (figs 2 and 3).
Bullous pemphigoid
Incidence
The crude incidence of bullous pemphigoid was 4.28
(95% confidence interval 4.01 to 4.58) per 100 000
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Fig 1 | Age atdiagnosis inpatientswithbullouspemphigoid and
pemphigus vulgaris
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Fig 2 | Kaplan-Meier curve for bullous pemphigoid, showing
mortality over time since diagnosis or “pseudodiagnosis” and
number of patients remaining in study
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person years. Incidence increased with age (table 1)
and in later calendar periods (fig 4). The increased
incidenceover calendar timepersistedafter adjustment
for age group and sex (P for trend <0.0001). The
estimated increase in the incidence of bullous pemphi-
goid per increase in calendar year was 17% (rate ratio
1.17, 95% confidence interval 1.14 to 1.20; P<0.0001)
after adjustment for sex and age group, corresponding
to a 4.8-fold increase in incidence over the 11 year
period or a crude increase of 5.2-fold during the study.
As we found no association with Townsend scores
and geographical regions, we excluded these from
multivariate regression.We foundnoevidenceof effect
modification to suggest that this trendwas confined to a
particular sex, age group, or region. Applying this data
to the UK population between 2001 and 2005 gave an
averageof2996 (95%confidence interval 2485 to3602)
new cases a year.
Mortality
Two hundred and sixty four deaths occurred in the
bullous pemphigoid cohort and 604 in the controls,
corresponding to an overall crude mortality of 131.99
(95% confidence interval 116.96 to 148.95) per 1000
person years for bullous pemphigoid and 61.86 (57.12
to 66.99) per 1000 person years for controls (table 2).
The absolute excess mortality in the bullous pemphi-
goid cohortwas70per1000personyears.Theoneyear
mortality for bullous pemphigoid was 19% (95%
confidence interval 16.2% to 21.8%). These data
Table 1 | Univariate andmultivariate analysis of incidence of bullous pemphigoid per 100 000person years,with threemonth lag
period to define incident cases
Variable Person years Events
Incidence per 100 000
person years Crude rate ratios
Mutually adjusted
incidence rate ratios
Likelihood
ratio tests
Sex: 0.63
Male 9 851 101 335 3.4 (3.1 to 3.8) 1.0 1.0
Female 10 400 000 534 5.1 (4.7 to 5.6) 1.5 (1.3 to 1.7) 1.0 (0.9 to 1.2)
Age group (years): <0.001*
<50 11 300 542 57 0.5 (0.4 to 0.7) 1.0 1.0
50-59 3 128 474 48 1.5 (1.2 to 2.0) 2.9 (2.0 to 4.3) 2.9 (2.0 to 4.3)
60-69 2 601 248 96 3.7 (3.0 to 4.5) 7.3 (5.3 to 10.2) 7.2 (5.2 to 10.0)
70-74 993 535 94 9.5 (7.7 to 11.6) 18.6 (13.3 to 25.8) 18.8 (13.5 to 26.1)
75-79 878 348 141 16.1 (13.6 to 18.9) 31.6 (32.2 to 43.0) 32.0 (23.5 to 43.5)
80-84 767 411 174 22.7 (19.5 to 26.3) 44.4 (32.9 to 60.0) 42.4 (31.4 to 57.3)
85-89 355 633 136 38.2 (32.3 to 45.2) 73.6 (53.9 to 100.4) 73.0 (53.5 to 99.7)
>90 266 833 123 46.1 (38.6 to 55.0) 91.4 (66.8 to 125.1) 86.4 (63.0 to 118.6)
Calendar period: <0.001*
1996-8 5 024 756 65 1.3 (1.0 to 1.6) 1.0 1.0
1999-2001 5 548 756 205 3.7 (3.2 to 4.2) 2.9 (2.2 to 3.8) 2.8 (2.1 to 3.7)
2002-4 5 975 951 351 5.9 (5.3 to 6.5) 4.5 (3.5 to 5.9) 4.2 (3.2 to 5.5)
2005-6 3 742 738 248 6.6 (5.9 to 7.5) 5.1 (3.9 to 6.7) 4.8 (3.6 to 6.3)
Townsend score: Not included
1 4 701 698 177 3.8 (3.2 to 4.4) 1.0
2 4 049 263 197 4.9 (4.2 to 5.6) 1.3 (1.0 to 1.6)
3 3 909 720 170 4.3 (3.7 to 5.1) 1.2 (0.9 to 1.4)
4 3 433 206 156 4.5 (3.9 to 5.3) 1.2 (1.0 to 1.5)
5 2 458 831 103 4.2 (3.5 to 5.1) 1.1 (0.8 to 1.4)
Missing 1 739 483 66 3.8 (3.0 to 4.8) 1.0 (0.8 to 1.3)
Region: Not included
East 1 717 944 79 4.6 (3.7 to 5.7) 1.0
East Midlands 1 020 922 52 5.1 (3.9 to 6.7) 1.1 (0.8 to 1.6)
London 2 350 474 76 3.2 (2.6 to 4.0) 0.7 (0.5 to 1.0)
North east 573 639 17 3.0 (1.8 to 4.8) 0.6 (0.4 to 1.1)
North west 2 322 677 90 3.9 (3.2 to 4.8) 0.8 (0.6 to 1.1)
Northern Ireland 687 514 29 4.2 (2.9 to 6.1) 0.9 (0.6 to 1.4)
Scotland 1 168 950 49 4.2 (3.2 to 5.5) 0.9 (0.6 to 1.3)
South east 3 863 908 175 4.5 (3.9 to 5.3) 1.0 (0.8 to 1.3)
South west 2 015 823 145 7.2 (6.1 to 8.5) 1.6 (1.2 to 2.1)
Wales 1 329 337 52 3.9 (3.0 to 5.1) 0.9 (0.6 to 1.2)
West Midlands 2 024 450 63 3.1 (2.4 to 4.0) 0.7 (0.5 to 0.9)
Yorkshire 1 216 563 42 3.5 (2.6 to 4.7) 0.7 (0.5 to 1.1)
*P for trend.
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correspond to a hazard ratio of 2.11 (95% confidence
interval 1.82 to 2.44).After adjustment for age, sex, and
calendar period, this increased to 2.29 (1.98 to 2.65).
We found no evidence of effect modification by
calendar time, as the hazard ratios comparing disease
cohorts with controls for each period were similar
(table 3 and fig 2).
Pemphigus vulgaris
Incidence
The crude incidence of pemphigus vulgaris was 0.68
(0.58 to 0.80) per 100 000 person years. Incidence was
higher in women and in older age groups (fig 1 and
table 4). We found evidence of an estimated 11%
increase in incidence per calendar year (incidence rate
ratio 1.11 (1.04 to 1.17) per year; P=0.001) (fig 4). We
saw a slight reduction in incidence in the most recent
period from3.5 (1.9 to6.2) in2002-4 to2.4 (1.2 to4.5) in
2005-6 (table 4). Applying these data to the UK
population between 2001 and 2005 gave an average of
467 (297 to 643) new cases of pemphigus vulgaris a
year.
Mortality
Thirty six deaths occurred in the pemphigus vulgaris
cohort and 58 deaths in controls, corresponding to an
overall crudemortalityof 94.64 (68.268 to131.205)per
1000 person years for pemphigus vulgaris and 32.89
(25.43 to 42.55) per 1000 person years for controls
(table 2). The absolute excess mortality in the
pemphigus vulgaris cohort was 62 per 1000 person
years. The one year mortality for pemphigus vulgaris
was 12% (8% to 19%), and the corresponding hazard
ratio was 2.82 (1.86 to 4.27).We saw no deaths in cases
aged less than 50 years, so we took the 50-59 year age
group as the baseline group for multivariate analyses.
After adjustment for sex, calendar period, and age
group, the hazard ratio for death in cases increased
markedly to 3.38 (2.21 to 5.17) (fig 2).
Comparison with Office for National Statistics mortality
data
Applying themortality data to the UK population data
gave 1977 deaths in bullous pemphigoid cases and 221
deaths in pemphigus vulgaris cases (2001-5). These are
much higher figures than the 190 and 36 deaths
attributed to these diseases in the Office for National
Statistics dataset.
DISCUSSION
We found a substantial increase in the incidence of both
bullous pemphigoid and pemphigus vulgaris between
1996and2005.This increasewasnotassociatedwithany
reduction in mortality over the calendar periods and is
therefore unlikely to be explained by ascertainment bias
leading to the diagnosis of less severe cases. Our study
therefore suggests that almost 3000 new cases of bullous
pemphigoid and 500 of pemphigus vulgaris occur each
year. Age and sex adjusted mortality was more than
twice as high in people with bullous pemphigoid
compared with the general population and three times
as high in thosewith pemphigus vulgaris. These diseases
are important causes of death; the Office for National
Statistics dataset reports 190 deaths from bullous
pemphigoid and 36 deaths from pemphigus vulgaris
between 2001 and 2005. The reported mortality for
bullous pemphigoid increased from 63 to 88 per 1000
person years between 2001 and 2005, and that for
pemphigus vulgaris increased from 13 to 19 per 1000
personyears.Applying themortalitydata fromourstudy
to the Office for National Statistics population gives a
much higher estimate of 2198 deaths between both
diseases in theUKbetween 2001 and 2005, althoughwe
did not measure the underlying cause of death.
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Table 2 | Crude and adjusted survival analysis for patientswith bullous pemphigoid and
pemphigus vulgaris
Deaths Person years
Crude hazard ratio
(95% CI)
Adjusted hazard ratio
(95% CI)
Bullous pemphigoid
Controls 604 9765 1.0 1.0
Cases 264 1993 2.11 (1.82 to 2.44) 2.29 (1.98 to 2.65)
Pemphigus vulgaris
Controls 58 1763 1.0 1.0
Cases 36 380 2.82 (1.86 to 4.27) 3.38 (2.21 to 5.17)
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Fig 3 | Kaplan-Meier curve for pemphigus vulgaris, showing
mortality over time since diagnosis or “pseudodiagnosis” and
number of patients remaining in study
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Strengths and weaknesses
This is a large, population based study, which allows
robust estimation of incidence and mortality. This is
less susceptible to selection bias than other study
designs and allows prospective study of disease trends
over time. The size of the dataset gives sufficient power
to exclude chance as the basis for the findings. The use
of routinely collected data means that we could not
validate the diagnoses or assess severity of disease.
These diagnoses are made in secondary care, usually
with skin biopsies and immunofluorescent techniques
to confirm the clinical diagnosis; they are therefore
likely to be accurate. Both bullous pemphigoid and
pemphigus vulgaris are uncommonly seen in general
practice, and general practitioners are highly unlikely
to record these diagnoses without referring to second-
ary or tertiary care. The potentially catastrophic
consequences of giving corticosteroids or other immu-
nosuppressants to people with infective causes of
blistering mean that appropriate investigations are
Table 3 | Hazard rates for death by calendar period comparing
bullous pemphigoid and pemphigus vulgaris with controls
Calendar period
Hazard ratio (95% CI)
Bullous pemphigoid Pemphigus vulgaris
1996-8 2.15 (1.47 to 3.15) 2.11 (0.66 to 6.72)
1999-2001 1.72 (1.32 to 2.24) 2.42 (1.13 to 5.17)
2002-4 2.34 (1.88 to 2.90) 3.43 (1.92 to 6.11)
2005-6 2.97 (1.87 to 4.72) 8.75 (0.79 to 96.52)
Table 4 | Univariate andmultivariate analysis of incidence of pemphigus vulgaris per 100 000person years,with threemonth lag
period to define incident cases
Variable Person years Events
Incidence per 100 000
person years Crude rate ratios
Mutually adjusted
incidence rate ratios
Likelihood
ratio tests
Sex: 0.02
Male 9 851 101 47 0.5 (0.4 to 0.6) 1.0 1.0
Female 1 040 000 91 0.9 (0.7 to 1.1) 1.8(1.3 to 2.6) 1.5 (1.1 to 2.2)
Age group (years): <0.001*
<50 11 300 542 34 0.3 (0.2 to 0.4) 1.0 1.0
50-59 3 128 474 16 0.5 (0.3 to 0.8) 1.8 (1.0 to 3.2) 1.7 (1.0 to 3.2)
60-69 2 601 248 18 0.7 (0.4 to 1.1) 2.2 (1.2 to 4.0) 2.2 (1.2 to 4.0)
70-74 993 535 11 1.1 (0.6 to 2.0) 3.8 (1.9 to 7.5) 3.7 (1.9 to 7.4)
75-79 878 348 16 1.8 (1.1 to 3.0) 6.2 (3.4 to 11.3) 6.1 (3.4 to 11.2)
80-84 767 411 20 2.6 (1.7 to 4.0) 8.9 (5.1 to 15.6) 8.2 (4.7 to 14.4)
85-89 355 633 13 3.7 (2.1 to 6.3) 12.5 (6.6 to 23.8) 11.4 (6.0 to 21.8)
>90 266 833 10 3.7 (2.0 to 7.0) 12.8 (6.3 to 26.0) 11.1 (5.4 to 22.6)
Calendar period: 0.002*
1996-8 5 024 756 14 0.3 (0.2 to 0.5) 1.0 1.0
1999-2001 5 548 756 37 0.7 (0.5 to 0.9) 2.4 (1.3 to 4.4) 2.4 (1.3 to 4.4)
2002-4 5 975 951 60 1.0 (0.8 to 1.3) 3.6 (2.0 to 6.5) 3.5 (1.9 to 6.2)
2005-6 3 742 738 27 0.7 (0.5 to 1.1) 2.6 (1.4 to 4.9) 2.4 (1.2 to 4.5)
Townsend score: Not included
1 4 701 698 33 0.7 (0.5 to 1.0) 1.0
2 4 049 263 18 0.4 (0.3 to 0.7) 0.6 (0.4 to 1.1)
3 3 909 720 32 0.8 (0.6 to 1.2) 1.1 (0.7 to 1.8)
4 3 433 206 20 0.6 (0.4 to 0.9) 0.8 (0.5 to 1.4)
5 2 458 831 19 0.8 (0.5 to 1.2) 1.2 (0.7 to 2.0)
Missing 1 739 483 16 0.9 (0.6 to 1.5) 1.3 (0.7 to 2.4)
Region: Not included
East 1 717 944 13 0.8 (0.4 to 1.3) 1.0
East Midlands 1 020 922 2 0.2 (0.0 to 0.8) 0.3 (0.1 to 1.1)
London 2 350 474 18 0.8 (0.5 to 1.2) 1.0 (0.5 to 2.1)
North east 573 639 5 0.9 (0.4 to 2.1) 1.2 (0.4 to 3.2)
North west 2 322 677 9 0.4 (0.2 to 0.7) 0.5 (0.2 to 1.2)
Northern Ireland 687 514 7 1.0 (0.5 to 2.1) 1.3 (0.5 to 3.4)
Scotland 1 168 950 3 0.3 (0.1 to 0.8) 0.3 (0.1 to 1.2)
South east 3 863 908 30 0.8 (0.5 to 1.1) 1.0 (0.5 to 2.0)
South west 2 015 823 27 1.3 (0.9 to 2.0) 1.8 (0.9 to 3.4)
Wales 1 329 337 3 0.2 (0.1 to 0.7) 0.3 (0.1 to 1.0)
West Midlands 2 024 450 15 0.7 (0.4 to 1.2) 1.0 (0.5 to 2.1)
Yorkshire 1 216 563 6 0.5 (0.2 to 1.1) 0.7 (0.2 to 1.7)
*P for trend.
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very likely to be carried out in secondary or tertiary
care to confirm the diagnosis. We were also able to
confirm that 94% of our cases were being treated with
either oral or potent topical corticosteroids or a
relevant steroid sparing agent after diagnosis or had
evidence of referral to hospital, which further supports
the validity of the diagnoses. Previous studies of other
conditions have confirmed the validity of diagnoses in
both the general practice research database and the
health improvement network.14 15 18 Limiting the data-
set to practices considered “up to standard” will have
improved the quality of data, as retrospective collec-
tion and coding of data is no longer a problem. Someof
the cases included may be prevalent rather than
incident cases, however. If this is the case, the results
may be affected by survival bias and we may have
underestimated the mortality associated with these
diseases; so the true mortality may be even higher.
Comparison with other studies
The mean age of patients with bullous pemphigoid in
our study is similar to other published data. However,
with the exception of one regional study, all studies
werehospital based; therefore, although theymayhave
had excellent validity, they may be less representative
of the disease in the population.3 5-7 19 The mean age of
patients with pemphigus vulgaris in our study was
much higher than previous reports. However, no data
on the epidemiology of pemphigus vulgaris in western
Europe have been published and all of the studies are
from hospital centres in the form of either cross
sectional surveys or case series; these studies are
unlikely to give reliable population based
statistics.3 4 6 7 10 12 19-21
The incidence of bullous pemphigoid in our study is
similar to that described by Garcia-Doval and
colleagues3; the incidence of pemphigus vulgaris is
within the range of the previous papers, and the sex
distribution is also similar.9 10 12 The increasing trend in
incidence of bullous pemphigoid has not been
previously shown, but no studyhas looked at incidence
of bullous pemphigoid prospectively over time. A
possible explanation is increased ascertainment, but if
this is the case the increasing trend has not levelled off.
The number of consultant dermatologists in the UK
increased by 39% between 1998 and 2006. This may
have contributed to increased ascertainment but is
unlikely to explain completely the increased incidence
because of the acute, severe presentations of these
disorders.
One year mortality from bullous pemphigoid is
lower (19%) than previously described in studies from
Europe (25-41%) but is intermediate between those
described in the United States (11%) and Europe.35-7 19
Non-inclusion of patients in nursing homes is not a
likely explanation for this as almost all patients in
nursing homes are under the care of general practi-
tioners. Despite recent published literature showing
the similar efficacy of potent topical steroids and oral
corticosteroids for bullous pemphigoid, oral cortico-
steroids remain in widespread use and may therefore
contribute to high mortality.19 One year mortality for
pemphigus vulgaris is higher than that described in a
recent study of younger cases in Turkey (4.8%) but
lower than that described in a study from the United
States by Ryan and colleagues in 1971 (54%;mean age
of casesnot given).12 13Thedesignsused inbothof these
studies are highly susceptible to selection bias, and
drawing any robust conclusions from the findings is
difficult.
Interpretation and implications
Our study shows that ratesof bullouspemphigoid seem
tobe increasingover time.Rates of pemphigus vulgaris
are increasing to a lesser degree despite the facts that
both disorders are more common with increasing age
and that the multivariate analysis was adjusted for age.
Possible explanations include ascertainment bias,
misclassification, and a true increase in incidence. If
the last of these is true, further investigation is
warranted into the reasons for this, as it may provide
further insight into the causes of the disorders. The lack
of a socioeconomic gradient and major geographical
variation argues against the environment playing an
important role in causing the diseases.
Our study has shown high mortality associated with
these diseases; rates were twice that in the general
population in patients with bullous pemphigoid and
three times as high as in the general population in those
with pemphigus vulgaris. With the increasing age of
ourpopulation, themorbidity andmortality from these
diseases will increase. Previous measures have under-
estimated the burden of these diseases, in terms of both
incidence and risk of death.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Little is known about the epidemiology of bullous pemphigoid and pemphigus vulgaris
Bullous pemphigoid is known to be associated with high mortality; mortality of pemphigus
vulgaris in western Europe is not known
WHAT THIS STUDY ADDS
The incidencesofbullouspemphigoidandpemphigus vulgaris are increasing, but the reasons
for this are not clear
Mortality of bullous pemphigoid is twice that of the general population, and mortality of
pemphigus vulgaris is three times as high as in the general population
Previous measures may have underestimated the burden of these diseases, in terms of both
incidence and risk of death
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